Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.42 |
| ▸ | ABL1 | P00519 | 8/20 | 0.42 |
| ▸ | EGFR | P00533 | 8/20 | 0.42 |
| ▸ | HCK | P08631 | 8/20 | 0.42 |
| ▸ | SRC | P12931 | 8/20 | 0.42 |
| ▸ | KDR | P35968 | 8/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.42 |
| ▸ | MTOR | P42345 | 8/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.42 |
| ▸ | PRKDC | P78527 | 8/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.42 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030042 | 0.84 | ESR1 (0.61) | ESR1PIK3CDABL1EGFRHCK | |
| SCHEMBL4029642 | 0.83 | ESR1 (1.00) | ESR1PIK3CDABL1EGFRHCK | |
| SCHEMBL4026005 | 0.82 | ESR1 (1.00) | ESR1PIK3CDABL1EGFRHCK | |
| SCHEMBL4028322 | 0.80 | ESR1 (0.71) | ESR1PIK3CDABL1EGFRHCK | |
| SCHEMBL4029427 | 0.80 | ESR1 (0.64) | ESR1PIK3CDABL1EGFRHCK | |
| SCHEMBL4027904 | 0.76 | ESR1 (1.00) | ESR1PIK3CDABL1EGFRHCK | |
| SCHEMBL5411401 | 0.76 | ESR1 (0.72) | ESR1EGFRCMKLR1 | |
| SCHEMBL4025780 | 0.75 | ESR1 (0.97) | ESR1PIK3CDABL1EGFRHCK | |
| SCHEMBL4033707 | 0.75 | ESR1 (0.73) | ESR1EGFRCMKLR1 | |
| SCHEMBL4027899 | 0.74 | ESR1 (0.80) | ESR1PIK3CDABL1EGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885PIK3CD 2619/4885ABL1 1218/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | ESR1 2487/4885PIK3CD 2207/4885ABL1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.